Why Actinium Pharmaceuticals, Inc.’s (ATNM) Stock Is Down 5.09%
As of Monday, October 27, Actinium Pharmaceuticals, Inc.’s ATNM share price has dipped by 5.09%, which has investors questioning if this is right time to buy.Cynthia McLaughlin
Stock Evaluator: Actinium Pharmaceuticals, Inc. (ATNM)
Actinium Pharmaceuticals, Inc. ATNM
$1.10
-0.02
-1.79%
August 21, 2026 4:00:00 PM
EST
Volume: 143,849
After Hours: $120.37
0.15
|
0.12%
November 10, 2021 7:59 PM
EST
Volume: 72,713
USD
AMEX | DELAYED PRICE
| SECTOR | INDUSTRY |
| Health Care | Biotechnology |
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Actinium Pharmaceuticals, Inc. develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. The company offers Actimab-A, a CD33 targeting radiotherapeutic for patients with Relapsed/Refractory AML which is in to a Phase 2/3 Trial; and Iomab-ACT, to improve patient access to and outcomes with cellular therapies, such as CAR-T and gene therapies for non-malignant hematologic disorders such as sickle cell disease. It also develops ATNM-400, a antibody radioconjugate that deliver alpha-emitter Ac-225 to prostate cancer cells. In addition, the company's Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with relapsed and refractory acute myeloid leukemia. Further, it engages with the National Cancer Institute under the cooperative research and development agreement for the development of Actimab-A in AML and other myeloid malignancies, and its research and development activities primarily focus on advancing various preclinical programs for solid tumor indications. The company is based in New York, New York.
Commentary & Analysis
Why Actinium Pharmaceuticals, Inc.’s (ATNM) Stock Is Down 5.33%
As of Friday, September 05, Actinium Pharmaceuticals, Inc.’s ATNM share price has dipped by 5.33%, which has investors questioning if this is right time to buy.Jenna Brashear
Why Actinium Pharmaceuticals, Inc.’s (ATNM) Stock Is Up 6.83%
As of Wednesday, July 30, Actinium Pharmaceuticals, Inc.’s ATNM share price has surged by 6.83%, which has investors questioning if this is right time to sell.Jenna Brashear
Why Actinium Pharmaceuticals, Inc.’s (ATNM) Stock Is Down 5.88%
As of Thursday, July 24, Actinium Pharmaceuticals, Inc.’s ATNM share price has dipped by 5.88%, which has investors questioning if this is right time to buy.Cynthia McLaughlin
Why Actinium Pharmaceuticals, Inc.’s (ATNM) Stock Is Up 7.72%
As of Friday, July 18, Actinium Pharmaceuticals, Inc.’s ATNM share price has surged by 7.72%, which has investors questioning if this is right time to sell.Jenna Brashear
Financial Summary
| Share Statistics | ATNM | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $34.6 | $292.6 | 13% |
|
| Shares Out (Mil) | 31.4 | 54.4 | 38% |
|
| Institutional Ownership | 96.6% | 93.2% | 70% |
|
| Float (Mil) | 31.3 | 40.2 | 37% |
|
| Beta | 0.02 | 0.94 | 7% |
|
| Avg Daily Volume (000s) | 237 | 544 | 46% |
|
| Price Change (52-week) |
(32.9%) | 59.7% | 21% |
|
| Growth | ATNM | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 13.6% | na |
|
| Net Income (5yr) | (8.8%) | (10.1%) | 30% |
|
| EPS (5yr) | 9.9% | 16.0% | 46 |
|
| Dividends (5yr) | na | 0.0% | 0% |
|
| Cash Flow (5yr) | (16.9%) | (15.6%) | 42% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 2 | 2 | 2 | |
| Current EPS | ($0.255) | $0.140 | ($0.525) | |
| Month Ago EPS | ($0.240) | ($0.910) | ($0.350) | |
| # Rev Up | 1 | 0 | 0 | |
| # Rev Down | 0 | 1 | 1 | |
| Three Months Ago EPS | ($0.235) | ($0.840) | ($0.477) | |
| Year/Year Chg | (128.7%) | (112.9%) | (52.1%) | |
| Financials | ATNM | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $35 | $37 | 17% |
|
| Net Income (TTM) (Mil) | $11 | ($43) | 46% |
|
| EPS (TTM) | $0.362 | ($1.400) | 51% |
|
| Operating Cash Flow (TTM) (Mil) | ($23) | ($31) | 14% |
|
| Net Cash Flow (TTM) (Mil) | na | $2 | na |
|
| Long-Term Debt (Q1) (Mil) | $1 | $4 | 15% |
|
| Enterprise Value (Q1) (Mil) | ($9) | $164 | 2% |
|
| Valuation | ATNM | Industry Median |
Percentile (All Stocks) |
|
| P/B | 1.15 | 2.83 | 26% |
|
| P/E | 3.1 | 19.6 | 3% |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | 0.3 | 1.0 | 14% |
|
| Ratios | ATNM | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 100.0% | 64.2% | 96% |
|
| Net Margin | 32.2% | (75.9%) | 90% |
|
| ROA | 21.9% | (47.5%) | 97% |
|
| ROE | 45.9% | (55.0%) | 92% |
|
| Liabilities to Assets | 24.5% | 29.6% | 17% |
|
| F-Score | 2 | 3 | 7% |
|
Passing Stock Screens
As of 8/21/2026, from a list of 60 stock screening strategies,
FACTOR STRATEGY
Fundamental Rule of Thumb Screen
Factors: Value
An old value screen combining the P/E ratio, dividend yield, and an adjusted return on equity that's still applicable in today's market.
| Performance Since Inception: | 6.6% |
| +/- S&P 500: | -0.9 |
